Transgene SA TNG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNG is a good fit for your portfolio.
News
-
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024
-
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
-
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
-
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
-
Transgene Announces Upcoming Investor Meetings
-
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
-
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Trading Information
- Previous Close Price
- €1.35
- Day Range
- €1.27–1.35
- 52-Week Range
- €1.03–2.55
- Bid/Ask
- €1.27 / €1.31
- Market Cap
- €129.09 Mil
- Volume/Avg
- 50,816 / 38,937
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 112.31
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 158
- Website
- https://www.transgene.fr
Comparables
Valuation
|
Metric
|
TNG
|
IMU
|
IMGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.54 | 3.05 | 14.78 |
Price/Sales | 112.31 | — | 28.51 |
Price/Cash Flow | — | — | — |
Price/Earnings
TNG
IMU
IMGN
Financial Strength
|
Metric
|
TNG
|
IMU
|
IMGN
|
|---|---|---|---|
Quick Ratio | 1.70 | 5.46 | 5.52 |
Current Ratio | 1.79 | 5.73 | 5.70 |
Interest Coverage | −131.90 | — | −7.68 |
Quick Ratio
TNG
IMU
IMGN
Profitability
|
Metric
|
TNG
|
IMU
|
IMGN
|
|---|---|---|---|
Return on Assets (Normalized) | −48.94% | −41.83% | −9.35% |
Return on Equity (Normalized) | −86.44% | −45.23% | −15.70% |
Return on Invested Capital (Normalized) | −79.12% | −47.05% | −14.37% |
Return on Assets
TNG
IMU
IMGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sxhmcpjp | Lxyj | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lvxvxhsm | Kxhvnf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hmpcdnrz | Vvdwxg | $99.5 Bil | |
MRNA
| Moderna Inc | Vlclkhf | Lzxls | $38.8 Bil | |
ARGX
| argenx SE ADR | Vkfkkhhr | Mptg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wbjgnnnmf | Lgzy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wpzsfxqf | Sksdvp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lfjfqwgnz | Fndkf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gkqvcknkj | Hkywpw | $12.5 Bil | |
INCY
| Incyte Corp | Gqypbbtc | Dqygtw | $11.6 Bil |